CAJ | 학술논문

目的研究XELOX方案一线治疗局部进展期、转移性的疗效及安全性.方法经组织学证实的局部进展期、转移性或复发胃癌胃腺癌患者41例,接受XELOX方案化疗(奥沙利铂130 mg/m~2,静脉滴注3h,第1天,卡培他滨1000mg/m~2,口服,2次/d,第1～14天,每3周重复).每2周期后进行疗效评价.中位治疗4个周期.结果 41例接受XELOX方案一线治疗的患者中.4例不可评价,CR2例,PR 15例,总有效率为41.5%,SD11例,PD9例.中位疾病进展时间为6.2个月,中位生存期达到11.8个月.XELOX方案治疗中导致3-4度毒性,其中神经毒性4例,手足综合征3例,血液学毒学4例.结论 XELOX方案作为一线治疗晚期或复发胃癌疗效肯定,毒副反应轻,患者耐受性好.
목적 연구XELOX방안일선치료국부진전기、전이성적료효급안전성.방법 경조직학증실적국부진전기、전이성혹복발위암위선암환자41례,접수XELOX방안화료(오사리박130 mg/m~2,정맥적주3h,제1천,잡배타빈1000mg/m~2,구복,2차/d,제1～14천,매3주중복).매2주기후진행료효평개.중위치료4개주기.결과 41례접수XELOX방안일선치료적환자중.4례불가평개,CR2례,PR 15례,총유효솔위41.5%,SD11례,PD9례.중위질병진전시간위6.2개월,중위생존기체도11.8개월.XELOX방안치료중도치3-4도독성,기중신경독성4례,수족종합정3례,혈액학독학4례.결론 XELOX방안작위일선치료만기혹복발위암료효긍정,독부반응경,환자내수성호.
Objective To evaluate the efficacy and toxicity of the combined therapy with oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent gastric cancer. Methods Forty-one patients with previously untreated advanced or recurrent gastric cancer received intravenous infusion of oxaliplatin at the dose of 130 mg/m~2 on day 1 and oral administration of capecitabine at 1000 mg/m~2 twice a day on days 1-14. The chemotherapy was repeated every 2 weeks for a median of 4 cycles. Results Two of 41 patients achieved a complete response, and 15 had partial responses, with an overall response rate of 41.5%. Stable disease was observed in 11 patients and progressive disease in 9. The median time to progression and overall survival was 6.2 months and 11.8 months. All the 41 patients were evaluated for toxicity according to NCI criteria, 4 showed grade 3-4 neural toxicity, 4 had hematological toxicity and 3 had hand-foot syndrome. Conclusion The XELOX regimen shows good efficacy with an acceptable toxicity profile in advanced or recurrent gastric cancer patient.